Kalkine ties the Canadian-listed company's move to its peptide therapy push, fresh funding and interest in the longevity market.
Recap by typeshit. Full story at kalkine.ca.
Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
Healio
Three months after the ADJUST-T1D trial ended, people who had been on semaglutide saw time in range drop 3.6 points, while those on placebo gained 1.5 points.
Trials showed low rates, while FAERS and EudraVigilance logged a wider range of events. The Warwick-linked authors call for standardized reporting and close monitoring.
Loading…